drugset / Trial / NCT04254419
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
NaSingle-groupOpen-labelTreatment
Summary
Each patient will receive up to 12 cycles of TGFβi NK cell infusions. Each cycle will be of 4 weeks duration. During the first 3 weeks, TGFβi NK cells will be infused once weekly. The 4th week will be a rest week. TGFβi NK cell infusions should be delivered at least 3 days apart (e.g., Friday of Week 1 and Monday of Week 2). Dose will be escalated in an inter-patient stepwise fashion consisting of 3 dose levels.
Timeline
- Start
- 2025-03-04
- Primary completion
- 2030-12-31
- Completion
- 2031-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TROCULEUCEL | Cell therapy | 3 ml | Other |